Last updated: April 25, 2026
Who Supplies Citalopram Hydrobromide to Pharma Markets?
Citalopram hydrobromide is a widely used branded and generic SSRI active pharmaceutical ingredient (API). Supply is typically split across (1) API manufacturers (API/cGMP sites) and (2) finished-dose manufacturers that buy API and formulate tablets. Direct procurement lists are rarely public, but company footprints and regulatory filings show consistent, recurring supplier names across global markets.
API Suppliers and Major Brand-Channel Manufacturing Footprints
Below are recurring, regulator-recognized API and intermediate supply participants tied to citalopram manufacture and commercialization.
| Supplier / Manufacturer |
Corporate Footprint |
What they typically supply |
Market relevance signals |
| Luye Pharma |
China |
Citalopram-related API and generics supply network |
Luye is a recurring SSRI participant in global generic supply chains and API catalog channels. |
| Zhejiang Huahai Pharma |
China |
API manufacturing and development for multiple CNS drugs |
Huahai is an established API producer with broad CNS portfolios and multiple regulatory clearances across markets. |
| Hikma |
Global |
Generic finished doses and API-backed product supply (via integrated and partner networks) |
Hikma is a major generic finished-dose supplier for multiple SSRIs, including markets where citalopram is a standard product. |
| Sandoz |
Global |
Finished-dose generics (and platform API supply via network) |
Sandoz is a dominant generic brand in antidepressants; citalopram is routinely in national formularies. |
| Teva |
Global |
Finished-dose generics and supply chain scaling |
Teva is a major SSRI generic supplier across Europe and other regulated markets. |
| Mylan (Viatris) |
Global |
Finished-dose generics |
Citalopram is a standard long-running generic molecule in their portfolio. |
| Sun Pharma |
Global |
Finished-dose generics |
Sun’s antidepressant portfolio includes older SSRIs used for chronic maintenance. |
| Cipla |
Global |
Finished-dose generics |
Cipla supplies multiple oral antidepressants and relies on established API networks. |
| Dr. Reddy’s |
Global |
Finished-dose generics |
Dr. Reddy’s supplies oral generics in antidepressants category. |
| Zydus Lifesciences |
India |
Finished-dose generics |
Zydus is an established antidepressant supplier in generic markets. |
How Citalopram Hydrobromide Is Sourced in Practice
Supply chain structure for citalopram hydrobromide typically follows this pattern:
- API is manufactured at cGMP sites (often in India or China for cost-led supply, plus EU/US sites for certain contracts).
- Intermediates and salt formation can be handled by the API site or by specialized intermediate makers depending on the contract model.
- Salt form control matters: the commercial material is sold as citalopram hydrobromide, and suppliers document identity, polymorph/solid-state controls when applicable, residual solvents, and assay/impurity profiles.
Regulatory-Visibility Suppliers: What Public Sources Commonly Capture
Most public evidence about “who supplies” citalopram hydrobromide is captured through:
- WHO/EDQM-linked product listings (as finished-dose products) and the manufacturers named on dossiers.
- FDA and other agency public databases where generics list the applicant and manufacturing sites.
- EU centralized and national submissions where sites are disclosed for manufacture and batch release.
The practical takeaway for procurement is that supplier selection usually starts at finished-dose product manufacturers (contracting) and then maps backward to API manufacturing sites through dossier review and supplier qualification.
Finished-Dose Manufacturer Supply List (Market-Active Generic Brands)
These companies are consistent global SSRI generic suppliers where citalopram hydrobromide tablets are commonly marketed under multiple label strengths.
- Teva
- Sandoz
- Mylan (Viatris)
- Hikma
- Sun Pharma
- Cipla
- Dr. Reddy’s
- Zydus
- Luye Pharma (often through global generic partners and/or local finished-dose entities)
API Contract Supply Reality
For buyers seeking API directly, common procurement patterns are:
- Framework contracts with a small number of qualified API manufacturers for year-round supply.
- Dual-source strategies to cover outages, compliance changes, or customs disruptions.
- Solid-state and impurity controls aligned to pharmacopeial and regulatory expectations for citalopram hydrobromide.
Key Takeaways
- Citalopram hydrobromide supply is dominated by generic finished-dose manufacturers with established global distribution (Teva, Sandoz, Viatris, Hikma, Sun Pharma, Cipla, Dr. Reddy’s, Zydus).
- API sourcing is typically concentrated among Asian API manufacturing networks (examples include Luye Pharma and Zhejiang Huahai Pharma in the SSRI API supply ecosystem).
- Public procurement visibility is higher for finished-dose than for the underlying API site, so most supply assurance work starts with product dossier mapping to manufacturing locations.
FAQs
1) Is citalopram hydrobromide supplied mainly as an API or as finished tablets?
Both, but buyers often secure supply through finished-dose manufacturers for commercialization, while API procurement is handled by formulation/pharma developers via qualification of API sites.
2) Which regions dominate citalopram hydrobromide supply?
API cost-led supply is heavily concentrated in Asia, while finished-dose supply is global across EU, US, and other regulated markets.
3) Do suppliers differ by tablet strength or only by API?
Tablet strengths depend on formulation and packaging, but API identity and purity standards must remain consistent; many suppliers support multiple strengths under the same API grade specification.
4) What qualification documents matter most for citalopram hydrobromide API?
Assay and impurities, solvent residues, identity (including salt form), and solid-state controls where required, typically supported by GMP certificates and batch records.
5) How do companies secure continuity of supply for older SSRIs like citalopram?
They use dual-source API strategies plus long-running finished-dose supply agreements with global generic leaders.
References (APA)
[1] World Health Organization. (n.d.). List of prequalified pharmaceutical products. WHO. https://extranet.who.int/pqweb/
[2] European Directorate for the Quality of Medicines & HealthCare. (n.d.). EDQM and related data resources. EDQM. https://www.edqm.eu/
[3] U.S. Food & Drug Administration. (n.d.). Drugs@FDA. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
[4] European Medicines Agency. (n.d.). Medicines (search by substance). EMA. https://www.ema.europa.eu/
[5] Viatris. (n.d.). Product portfolio and generic medicines information. Viatris. https://www.viatris.com/
